Table 1.

Cell viability analysis of pyrazole derivatives in multiple cancer cell lines.

No.	Structure	Molecular weight	MCF7(20 μM)	U373(20 μM)	LN18(20 μM)	DLD-1(20 μM)	HCT116(20 μM)	A549(20 μM)	H1299(20 μM)
5a		395.40	33.01	14.17 ± 2.92	7.52 ± 0.22	10.9 ± 2.67	5.42 ± 4.86	20.62 ± 12.69	6.93 ± 2.63
5b (PCW-1001)		410.42	10.07 ± 10.01	8.71 ± 2.09	5.36 ± 0.49	7.93 ± 2.52	1.99 ± 0.81	14.69 ± 0.58	8.75 ± 6.86
6a		409.43	63.12 ± 4.04	48.21 ± 7.59	8.96 ± 1.16	12.48 ± 2.31	42.02 ± 2.85	68.63 ± 2.07	77.64 ± 8.26
6b		519.98	75.19 ± 15.33	104.45 ± 20.67	133.12 ± 13.04	109.24 ± 5.48	91.02 ± 6.71	153.97 ± 1.93	173.18 ± 17.17
6c		424.45	66.67 ± 3.7	46.02 ± 5.6	8.81 ± 1.15	9.77 ± 0.47	59.94 ± 3.31	90.42 ± 12.87	75.54 ± 7.2
6d		534.99	91.92 ± 1.48	67.44 ± 10.33	97.12 ± 0.23	82.68 ± 1.66	46.74 ± 6.94	109.21 ± 23.2	113.04 ± 6.93
8a		359.35	71.30 ± 29.98	72.10 ± 20.27	74.33 ± 7.37	62.66 ± 13.37	46.07 ± 8.68	89.69 ± 22.88	101.81 ± 3.66
8b		373.38	67.79 ± 35.61	65.09 ± 12.03	64.39 ± 6.64	40.25 ± 11.49	42.74 ± 1.39	86.63 ± 3.07	102.16 ± 6.03
8c		387.41	75.31 ± 29.06	68.12 ± 17.42	54.23 ± 9.92	34.83 ± 4.01	35.81 ± 0.99	93.43 ± 14.71	95.35 ± 1.78
9a		359.35	93.22 ± 14.36	96.66 ± 8.6	78.99 ± 11.63	76.95 ± 9.51	58.38 ± 6.74	135.48 ± 27.73	96.14 ± 1.57
9b		387.41	59.31 ± 2.8	92.20 ± 7.8	54.70 ± 6	54.59 ± 13.65	39.28 ± 8.65	70.38 ± 19.33	75.7 5 ± 1.57